Trial Profile
A multicenter, national, open-label, prospective, randomized study to evaluate efficacy and tolerability of enteric-coated mycophenolate sodium 1440 mg/day with tacrolimus reduced dose versus enteric-coated mycophenolate sodium 720 mg/day with tacrolimus standard dose, in maintenance, stable, adult, kidney transplant recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary) ; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 02 Feb 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.
- 01 Feb 2012 Planned number of patients (98) added as reported in Clinical Nephrology.
- 01 Feb 2012 Results published in the Clinical Nephrology.